Advanced Synovial Sarcoma — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033
Synovial sarcoma (SYN) is a soft tissue sarcoma, constituting about 5–14% of all soft tissue sarcomas. It typically manifests between the ages of 35 and 40, affecting both males and females equally. While SYN commonly originates in the deep tissues of the extremities, it can also occur in the head, neck, trunk, and lungs. With a historical five-year metastasis-free survival rate of 50–60%, SYN exhibits a high propensity for metastasis. First-line treatment for locally advanced or metastatic SYN typically involves anthracycline-based chemotherapy, with or without ifosfamide. SYN tumors are relatively responsive to chemotherapy compared to other soft tissue sarcomas. Currently, the standard approach for advanced synovial sarcoma involves anthracycline-based chemotherapy. Another FDA-approved systemic therapy for advanced or metastatic SYN is pazopanib.
- In the United States, SYN has an approximate incidence of 1.42 cases per million among adults and 0.81 cases per million among children and adolescents, amounting to around 1,000 cases annually.
Thelansis’s “Advanced Synovial Sarcoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced Synovial Sarcoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Advanced Synovial Sarcoma across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Advanced Synovial Sarcoma Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
